EuroBiotech—More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Affibody raised SEK 200 million ($24 million) in a rights issue. The Swedish biotech will use the cash to expand its clinical program. Release

> Roche became the latest biopharma to team up with BioMed X. The agreement will lead to the creation of an immune-mediated disease research group in Germany. Statement

> The U.K. committed cash to create cell and gene therapy centers designed to establish it as a go-to location for clinical trials for the emerging classes of medicine. Release 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Kinase inhibitor startup BCI Pharma raised cash to advance research projects in cancer, neuropathic pain, inflammation and neuro-inflammation. Statement

> Amryt Pharma licensed a non-viral gene therapy platform. The biotech plans to explore the use of the platform in the treatment of recessive dystrophic epidermolysis bullosa. Release

> The Norwegian National Ethics Board rejected BerGenBio’s request for retrospective approval of a phase 1/2b trial of AXL kinase inhibitor BGB324. The ongoing trial only involves sites in the U.S and is FDA cleared, leaving BerGenBio unsure of the implications of the ethics snafu in its home country. Statement

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.